ABSTRACT Background: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist that has significant effects on glycemic control and weight loss in patients with type 2 diabetes mellitus (T2DM) and obesity. Tirzepatide mimics the actions of both GIP and GLP-1, the main incretin hormones that regulate glucose homeostasis and energy balance. Materials and Methods: A systematic literature search was conducted for relevant articles published, using the terms “Tirzepatide,” “type 2 diabetes,” and “obesity.” Relevant studies were assessed for quality, and the data were extracted and synthesized using a narrative approach. Results: Tirzepatide significantly improved glycemic control and reduced body weight in patients with T2DM and obesity compared with placebo, insulin, or other GLP-1 receptor agonists, with a reduction in hemoglobin A1c and body mass index. Additional metabolic parameters that improved included blood pressure, lipid profile, and liver function tests. Tirzepatide was generally well tolerated, with the most common adverse effects being nausea, vomiting, and diarrhea. The incidence of hypoglycemia and serious adverse events was low and comparable with control treatments.
Musaliyar et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: